Younger haplo-donors improve older patient survival outcomes.
作者信息
Ghorab Ahmad, Luznik Leo
机构信息
Division of Hematology and Oncology, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, TX.
出版信息
Blood Adv. 2025 Jul 8;9(13):3308-3309. doi: 10.1182/bloodadvances.2025016335.
Abstract
摘要
相似文献
1
Younger haplo-donors improve older patient survival outcomes.
Blood Adv. 2025 Jul 8;9(13):3308-3309. doi: 10.1182/bloodadvances.2025016335.
2
Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation.
Blood Adv. 2025 Jul 8;9(13):3226-3237. doi: 10.1182/bloodadvances.2024014938.
3
Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients and Donors.
Transplant Cell Ther. 2024 Aug;30(8):808.e1-808.e13. doi: 10.1016/j.jtct.2024.05.018. Epub 2024 May 25.
4
Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant. 2024 Jul;59(7):983-990. doi: 10.1038/s41409-024-02275-6. Epub 2024 Mar 30.
5
Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Biol Blood Marrow Transplant. 2017 Oct;23(10):1736-1743. doi: 10.1016/j.bbmt.2017.06.019. Epub 2017 Jul 5.
6
Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings.
J Blood Med. 2025 Mar 30;16:151-161. doi: 10.2147/JBM.S511039. eCollection 2025.
7
Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis.
Blood Adv. 2025 Jul 22;9(14):3469-3478. doi: 10.1182/bloodadvances.2024014858.
8
Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors?
Curr Hematol Malig Rep. 2015 Mar;10(1):1-7. doi: 10.1007/s11899-014-0245-y.
9
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).
Transplant Cell Ther. 2024 Nov;30(11):1100.e1-1100.e11. doi: 10.1016/j.jtct.2024.08.023. Epub 2024 Sep 5.
10
Incidence, Risk Factors, and Outcomes of BK Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplantation From HLA-Matched and Haploidentical Donors With Post-Transplant Cyclophosphamide.
Transplant Cell Ther. 2025 Mar;31(3):182.e1-182.e11. doi: 10.1016/j.jtct.2024.12.006. Epub 2024 Dec 17.
本文引用的文献
1
Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation.
Blood Adv. 2025 Jul 8;9(13):3226-3237. doi: 10.1182/bloodadvances.2024014938.
2
In 2022, which is preferred: haploidentical or cord transplant?
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):64-73. doi: 10.1182/hematology.2022000327.
3
Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation for myelodysplastic syndrome: A retrospective study from the Adult Myelodysplastic Syndrome Working Group of the Japanese Society for Transplantation and Cellular Therapy (JSTCT).
Am J Hematol. 2022 Dec;97(12):E447-E450. doi: 10.1002/ajh.26722. Epub 2022 Sep 22.
4
Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.
Bone Marrow Transplant. 2022 Nov;57(11):1681-1688. doi: 10.1038/s41409-022-01770-y. Epub 2022 Aug 20.
5
Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning.
Blood Adv. 2021 Oct 26;5(20):4064-4072. doi: 10.1182/bloodadvances.2021004462.
6
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide.
Blood Adv. 2021 Mar 9;5(5):1360-1368. doi: 10.1182/bloodadvances.2020003922.
7
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy.
Blood Adv. 2020 Aug 25;4(16):3900-3912. doi: 10.1182/bloodadvances.2020001620.
8
Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide.
Blood Adv. 2018 Feb 13;2(3):299-307. doi: 10.1182/bloodadvances.2017014829.
9
Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.
Am J Hematol. 2018 Feb;93(2):246-253. doi: 10.1002/ajh.24963. Epub 2017 Dec 6.
10
Modern approaches to HLA-haploidentical blood or marrow transplantation.
Nat Rev Clin Oncol. 2016 Jan;13(1):10-24. doi: 10.1038/nrclinonc.2015.128. Epub 2015 Aug 25.
Zotero 插件